SUGAR-MGH is a pharmacogenetic resource for characterizing genetic influences on pharmacological perturbations relevant to type 2 diabetes (T2D). 1,000 participants who were naïve to T2D treatment received 5 mg glipizide, followed by 4 doses of 500 mg metformin and a 75-g oral glucose tolerance test (OGTT) a week later. Glucose and insulin were measured at pre-specified endpoints after glipizide and during the OGTT. Incretin levels were measured in a subset. We calculated physiologic endpoints reflecting insulin secretion, insulin sensitivity, and incretin secretion. The mean age was 47 years, 54% were women, >35% were non-white, and the mean BMI was 30.2 kg/m2. 890 participants underwent genome-wide genotyping using the Illumina Multi-Ethnic Genotyping Array, and high-quality imputation was performed with the TOPMed reference panel. Multiple linear regression using an additive model tested for association between genetic variants and endpoints. We identified 21 genome-wide significant variants, of which 3 met experiment-wide significance (P<8.3×10-9 for 2 drugs × 3 physiological hypotheses tested). The most significant association was between an African ancestry-specific variant (minor allele frequency=0.026) at rs149403252 and lower fasting glucose following metformin, adjusted for baseline glucose (P=1.9×10-9). We tested the influence of 429 known T2D-associated variants and found that the protective C allele of rs703972 near ZMIZ1 was associated with increased secretion of active GLP-1 in response to metformin (P=1.6×10-5), suggesting that an enhanced incretin response may be a mechanism by which this variant decreases T2D risk. We illustrate that a genome-wide approach in a multi-ethnic human perturbation study can uncover new variation associated with drug response and provide insight into mechanisms of action of known T2D genetic variation.

Disclosure

J. H. Li: None. V. Kaur: None. L. Brenner: Research Support; Self; Apple. J. M. Mercader: None. J. C. Florez: Consultant; Self; Goldfinch Bio, Inc., Other Relationship; Self; Novo Nordisk.

Funding

National Institutes of Health (R01DK088214, R03DK077675, P30DK036836, M01RR01066, 1UL1RR025758-04, 8UL1TR000170-05, T32DK007028)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.